The approval of the oral BTKi rests on a phase 3 result of 29.3% complete response from hives vs 14.0% with placebo at week 12.
Quiz|Articles|July 12, 2026
Dermatology Times Spot Test: July 12, 2026
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- A recurring quiz series is framed as a weekly mechanism to evaluate and reinforce dermatology knowledge across foundational concepts and new developments.
- This week’s clinical-news focus centers on Evommune updates relevant to chronic spontaneous urticaria.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Welcome to Dermatology Times' Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This week, we’ll focus on the latest news from
Do you have a set of quiz questions to share? Contact editor Marie Bosslett at
What was the primary outcome of Evommune's phase 2b trial of EVO756 in CSU?
Which mechanism of action best describes EVO756?
Approximately how many patients were enrolled in this phase 2b trial?
Advertisement
Related to this article
Celltrion’s US launch of omalizumab-igec adds an interchangeable biosimilar option for eligible patients with chronic spontaneous urticaria.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
The Value of Precision Medicine in Atopic Dermatitis and Skin Cancers
2
JAK Inhibitor Safety in Atopic Dermatitis: Long-Term Epidemiology Data
3
No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
4
HS Treatment Selection and Comorbidity Screening: Practical Tips With Jennifer Hsiao, MD
5